CNO treatment of Hep-Dq mice leads to pronounced increases in blood glucose levels. Using AAV technology (see text for details), we generated mice that expressed either Dq or EGFP selectively in hepatocytes (Hep-Dq and Hep-EGFP control mice, respectively). Male mice (genetic background: C57BL/6; age: ~12 weeks) that had been fasted overnight for 12 hr received a single injection of CNO (10 mg/kg i.p.), and blood glucose levels were measured at the indicated time points (M. Rossi, et al., unpublished results). Data are given as means ± SEM (n=8 per group).